FDA
-
-
-
-
-
-
-
Sanofi wins EU approval for Wayrilz to treat immune thrombocytopenia
-
-
-
-
-
-
-
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
-
-
-
-
-
-
-
Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
-
-
-
-
-
-
-
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
-
-
-
-
-
-
-
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
-
-
-
-
-
-
-
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans
-
-
-
-
-
-
-
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
-
324,023 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

